111

111 R&D Expenses

The Research & Development Expenses of 111 (YI) as of Oct 31, 2026 is 58.75 M CNY. In the previous year, Research & Development Expenses was 124.34 M CNY — a change of -52.75% (lower).

R&D Expenses

58.75 MCNY

YoY

-52.75%

Last updated:

Research & Development Expenses of 111 is 2025 58.75 M CNY. Research & Development Expenses of 111 was 2024 124.34 M CNY. It decreases by -52.75% lower compared to the previous year.

The 111 R&D Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D Expenses
Date
R&D Expenses
Jan 1, 2017
48.13 M CNY
Jan 1, 2018
71.25 M CNY
Jan 1, 2019
61.90 M CNY
Jan 1, 2020
92.08 M CNY
Jan 1, 2021
189.28 M CNY
Jan 1, 2022
139.50 M CNY
Jan 1, 2023
124.34 M CNY
Jan 1, 2025
58.75 M CNY
The 111 R&D Expenses history
YEARR&D ExpensesYoY
58.75 MCNY-52.75%
124.34 MCNY-10.87%
139.50 MCNY-26.30%
189.28 MCNY+105.56%
92.08 MCNY+48.75%
61.90 MCNY-13.12%
71.25 MCNY+48.02%
48.13 MCNY-22.07%
61.77 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

111 Stock analysis

What does 111 do? 111 Inc, trading under the ticker YI and ISIN US68247Q2012, is a company based in Shanghai, China, operating within the Consumer Staples sector and Retail industry. The company went public on September 12, 2018. According to the provided information, 111 Inc is engaged in the provision of pharmaceutical products and medical services through online retail pharmacy and an indirect offline pharmacy network. The company's website is http://gangling.111.com.cn/. The employee count provided in the user message is 144, though the source description mentions 1,932 full-time employees, which is inconsistent. The company focuses on online medical services, drug purchasing, and health management services utilizing internet and information technology. It primarily serves the domestic market in China. The company's headquarters are located in Shanghai, Shanghai, and it operates with a focus on retail and consumer staples within the pharmaceutical and healthcare services domain. 111 is one of the most popular companies on Eulerpool.

Frequently Asked Questions about 111 stock

Research & Development Expenses of 111 is 58.75 M CNY in 2025.

Research & Development Expenses of 111 changed from 124.34 M CNY to 58.75 M CNY, representing a -52.75% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Research & Development Expenses 111 since 2006 – with annual values, charts, and detailed analysis.

R&D expenses represent the costs incurred in researching and developing new products, services, or processes. High R&D spending can signal innovation and future growth potential.

Research & Development Expenses's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Research & Development Expenses's 111 historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — 111

All Key Metrics — 111